NCOA1 influences the effectiveness of tamoxifen in breast cancer treatment by modulating estrogen receptor signaling pathways, and variations in NCOA1 can lead to different clinical outcomes, necessitating personalized treatment approaches. In prostate cancer, NCOA1 affects responses to anti-androgen therapies by its role in androgen receptor signaling, although specific drugs are not mentioned.